4th Annual CME Symposium
This advanced continuing medical education activity, once again being held at the historic Hudson Theatre in New York City, will provide participants with state-of-the-art education and practical guidance from nationally and internationally recognized experts on hepatitis C virus infection.
The primary goals of this activity are to increase each frontline care provider's competence to:
- • Recognize the indications for treatment of HCV infection as well as areas of uncertainty in treatment
- • Explain barriers to effective care of patients with hepatitis C
- • Distinguish the recognition and treatment of acute HCV infection from that of chronic infection
- • Demonstrate the approach to diagnosis and treatment of hepatocellular carcinoma
- • Apply new information to manage disease in difficult-to-treat populations
- • Indicate new therapeutic drugs, pharmacology of HCV therapy, and resistance to treatments
As we enter the fourth year of HEPATITIS C MANAGEMENT: STATE OF THE ART, enormous progress continues to be made in the treatment of this disease. A rapidly increasing number of treatment options require practitioners to continually update their knowledge about the potential benefits and pharmacology of various hepatitis C therapies. These therapies, as well as their side effects and effectiveness, make the decision to treat individual patients more complex. They require the practitioner to possess a sophisticated understanding of the natural history of the disease, viral resistance to therapy, and management requirements of various patient populations with hepatitis C.
The state-of-the art curriculum offered at this activity is designed to meet the needs of hepatologists, gastroenterologists, infectious disease specialists, general practitioners, physician assistants, nurse practitioners, registered nurses, pharmacists and other frontline healthcare professionals involved in the management of patients with hepatitis C, including those with HCV/HIV coinfection.